drugset / Trial / NCT05170256
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
Phase 2
Unknown
24 enrolled
Morten Mau-Sørensen
Aalborg University Hospital · collabAarhus University Hospital · collabOdense University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The study aims to determine the efficacy of trastuzumab added to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab) in patients with HER2 positive Esophageal squamous cell carcinoma (ESCC) determined by 6 months progression free survival (PFS) (RECIST 1.1).
Timeline
- Start
- 2022-02-04
- Primary completion
- 2025-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | — |